# THE IMMUNOBIOLOGY OF HUMAN ANTILEUKEMIC LYMPHOCYTES

> **NIH NIH R01** · UNIVERSITY OF WISCONSIN-MADISON · 1989 · $133,447

## Abstract

The purpose of these studies is to examine the proliferative and cytotoxic
immune responses that can be demonstrated by culturing human lymphocytes
with HLA matched and mismatched leukemia cells and other abnormal
histocompatible cells in vitro.  This will be done using the mixed
lymphocyte culture (MLC), primed lymphocyte typing (PLT), and cell-mediated
lysis (CML) assays with primary, secondary, and cloned T-cell responses.

Leukemic blasts will be obtained from patients by bone marrow aspiration at
diagnosis and at relapse.  Cryopreserved blasts will be used as stimulating
and target cells in MLC and CML assays.  Responding cells in these cultures
will be autologous remission lymphocytes or lymphocytes from HLA identical
or haplo-identical relatives.  To facilitate studying antileukemic
responses, we will address methodological problems and immunologic
specificity utilizing model systems in which helper and cytotoxic responses
are stimulated by autologous lymphocytes that have been labeled with
bacterial antigen or transformed by the Epstein-Barr virus.

Our objectives are to:

(1) examine the induction requirements, antigenic specificity, and HLA
restriction of human lymphocytes primed in vitro to abnormal
histocompatible tissues;

(2) evaluate the potential relationship between this in vitro response in
the clinical course of leukemic patients, especially those who have just
received bone marrow transplants, with emphasis on factors that may
influence the ability to generate an "antileukemic" immune response; and

(3) generate large numbers of polyclonal and single cell-derived
populations of leukemia reactive T cells by in vitro expansion with
interleukin 2 containing T-cell growth factor in order to further examine
the specificity of these cells and generate the in vitro data required to
initiate clinical trials of adoptive cellular immunotherapy in
appropriately selected high-risk patients with leukemia and other
neoplasms.  (LB)

## Key facts

- **NIH application ID:** 3170551
- **Project number:** 5R01CA032685-08
- **Recipient organization:** UNIVERSITY OF WISCONSIN-MADISON
- **SAM.gov UEI:** LCLSJAGTNZQ7
- **Principal Investigator:** PAUL M SONDEL
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 1989
- **Award amount:** $133,447
- **Award type:** 5
- **Project period:** 1982-07-01 → 1990-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/3170551

## Citation

> US National Institutes of Health, RePORTER application 3170551, THE IMMUNOBIOLOGY OF HUMAN ANTILEUKEMIC LYMPHOCYTES (5R01CA032685-08). Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/grant/nih/3170551. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*